Royalty Pharma (RPRX) debt: $9B
Royalty Pharma had $9B of long-term debt on Dec 31, 2025, including the part due within a year, up 17.6% from $7.6B a year earlier.
From Royalty Pharma's filings with the SEC · Read the filing · RPRX stock page
Royalty Pharma debt by year
#195 of 2,129 US companies by debt · See the full ranking
| Year ended | Debt | Change |
|---|---|---|
| Dec 31, 2025 | $9B | +18% |
| Dec 31, 2024 | $7.6B | +24% |
| Dec 31, 2023 | $6.1B | -14% |
| Dec 31, 2022 | $7.1B | +0% |
| Dec 31, 2021 | $7.1B | – |
Debt of similar companies
Companies in the same industry as Royalty Pharma, by SEC industry code, with the closest debt. Each name opens the same page for that company.
| Company | Debt, latest year | Year ended |
|---|---|---|
| Bausch Health Companies | $20.8B | Dec 31, 2025 |
| Viatris | $14.4B | Dec 31, 2025 |
| Abbott Laboratories | $12.9B | Dec 31, 2025 |
| Zoetis | $9B | Dec 31, 2025 |
| Royalty Pharma | $9B | Dec 31, 2025 |
| Organon | $8.6B | Dec 31, 2025 |
| Jazz Pharmaceuticals | $5.4B | Dec 31, 2025 |
Questions and answers
What is Royalty Pharma's debt?
Royalty Pharma had $9B of long-term debt on Dec 31, 2025, including the part due within a year, up 17.6% from $7.6B a year earlier.
Numbers as reported in Royalty Pharma's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology